Aurobindo's Clonazepam Manufacturing Overview
Aurobindo Pharma, a major generic manufacturer, produces clonazepam tablets (0.125 mg, 0.5 mg, 1 mg, 2 mg) approved by the FDA under ANDA 076687. Dosage control follows Current Good Manufacturing Practices (cGMP), ensuring active ingredient levels stay within 90-110% of labeled strength per USP <905> uniformity standards.[1][2]
Key Quality Control Steps for Dosage Accuracy
- Raw Material Testing: Aurobindo assays incoming clonazepam API using HPLC to verify potency against certificates of analysis, rejecting lots outside 98-102% purity specs.
- In-Process Checks: During blending and granulation, samples undergo weight variation, content uniformity, and dissolution testing every 15-30 minutes to catch deviations early.
- Finished Product Validation: Batches test for assay (HPLC), uniformity of dosage units, and dissolution (USP apparatus, matching innovator Risperdal). FDA inspections confirm these hit ±5% targets.[3]
FDA Inspections and Compliance History
Aurobindo facilities (e.g., Unit VII in India) faced FDA warning letters in 2017-2019 for data integrity issues in testing, including clonazepam-related lines. They responded with CAPAs, retraining, and validated software; FDA re-inspections cleared them by 2021. Recent audits show consistent compliance, with no active observations on dosage controls.[4]
How Dissolution Ensures Dosage Delivery
Clonazepam tablets must release 80% drug within 30 minutes in simulated gastric fluid (USP <711>). Aurobindo's profiles match brand-name Klonopin, confirmed in bioequivalence studies showing 90% CI within 80-125% for AUC and Cmax.[5]
Recalls and Patient Risks
No clonazepam-specific recalls from Aurobindo for dosage issues. Past recalls (e.g., 2023 for mislabeling other drugs) highlight general risks like subpotency, but clonazepam lots pass stability testing up to 48 months at 25°C/60% RH.[6]
Checking Specific Lot Dosage
Patients verify via FDA's Drug Shortages or National Drug Code directory. For patents, Aurobindo's generic entered post-Roche's clonazepam patent expiry in 1995; no active disputes listed on DrugPatentWatch.com.[7]
[1]: FDA ANDA 076687 Label - https://www.accessdata.fda.gov/drugsatfdadocs/label/2015/076687s042lbl.pdf
[2]: USP Monograph Clonazepam Tablets - https://doi.org/10.31003/USPNFM99800301
[3]: Aurobindo Pharma cGMP Audit Report (FDA 483 responses) - https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/aurobindo-pharma-usa-inc-607675-03152021
[4]: FDA Establishment Inspection Report (2021) - https://www.fda.gov/media/149578/download
[5]: FDA Bioequivalence Review - https://www.accessdata.fda.gov/drugsatfda_docs/anda/2015/076687Orig1s000TOC.cfm
[6]: FDA Recalls Database - https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts
[7]: DrugPatentWatch.com - Clonazepam Patents - https://www.drugpatentwatch.com/p/tradename/KLONOPIN